Di Cesare, A. (2025) “Therapeutic Modulation Of Peripheral Blood Cells And Inflammatory Indices During 52 Weeks Of Risankizumab In Responder Patients With Moderate-to-Severe Psoriasis: Results From A Multicenter Prospective Study”, Dermatology Practical & Conceptual, 15(4), p. 5733. doi:10.5826/dpc.1504a5733.